40 Participants Needed

Stem Cell Therapy for Spinal Cord Injury

No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to investigate the safety and potential therapeutic effects of autologous, culture-expanded, adipose derived mesenchymal stem cell intrathecal injections in the treatment of spinal cord injury.

Will I have to stop taking my current medications?

The trial requires that you stop taking certain medications, such as anti-rheumatic drugs and systemic steroids, at least 3 months before enrolling. If you are currently on chronic immunosuppressive therapy or taking riluzole for ALS, you will not be eligible to participate.

What data supports the effectiveness of the treatment for spinal cord injury?

Research shows that using adipose-derived stem cells (cells taken from fat tissue) can help improve recovery in spinal cord injury. Studies in rats and some human cases have shown that these cells can aid in functional recovery, suggesting potential benefits for patients with spinal cord injuries.12345

Is stem cell therapy using adipose-derived mesenchymal stem cells safe for humans?

In a clinical trial, a patient with a spinal cord injury received adipose-derived mesenchymal stem cells and tolerated the procedure well without any severe adverse events, suggesting it is safe for humans.12367

How is the treatment with Autologous Adipose Derived Mesenchymal Stem Cells different from other treatments for spinal cord injury?

This treatment is unique because it uses stem cells derived from a patient's own fat tissue, which are then infused back into the body to help repair spinal cord damage. Unlike other treatments, it focuses on using the body's own cells to promote healing and regeneration, offering a personalized approach to recovery.12347

Research Team

MB

Mohamad Bydon, MD

Principal Investigator

Mayo Clinic

Eligibility Criteria

Adults aged 18+ with traumatic, non-penetrating spinal cord injuries (SCI) graded A or B at injury time, who've seen no significant improvement for a year. Participants must understand and commit to the study's requirements including home exercises and follow-ups. Women of childbearing age need a negative pregnancy test and must use contraception during the study.

Inclusion Criteria

I am not pregnant, can use birth control, and am of childbearing age.
My spinal cord injury was severe at first but improved within a year, though it has not gotten better since.
If a woman becomes pregnant during the study, she will be closely watched to make sure both she and the baby are healthy. Any serious issues related to the pregnancy will be noted.
See 6 more

Exclusion Criteria

I have taken medication for rheumatic disease in the last 3 months.
I have had treatments involving stem cells, gene therapy, or exosomes.
I can have an MRI and am willing to undergo MRI procedures.
See 19 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients receive a single dose of autologous, adipose derived mesenchymal stem cells

1 day
1 visit (in-person)

Observation

Patients are observed over six months while attending physical and occupational therapy

6 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

12 months

Treatment Details

Interventions

  • Autologous Adipose Derived Mesenchymal Stem Cells
  • Best Medical Management: Occupational and Physical Therapy
Trial OverviewThe trial is testing if one's own adipose-derived mesenchymal stem cells can safely improve SCI outcomes when injected into the spinal fluid, alongside standard occupational and physical therapy treatments.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: Treatment Group 1: AD-MSC InjectionExperimental Treatment1 Intervention
Patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.
Group II: Treatment Group 2: Best Medical ManagementActive Control2 Interventions
Patients will be observed over six months while attending physical and occupational therapy. After six months, patients will receive a single dose of autologous, adipose derived mesenchymal stem cells one time. The cells are isolated from patient's adipose tissue and expanded for intrathecal delivery.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Findings from Research

Intravenous transplantation of adipose-derived stem/stromal cells (ASCs) in rats with spinal cord injury (SCI) led to improved functional recovery and reduced spinal cord damage, although the long-term survival of the transplanted cells was not achieved.
The study identified that the cytokine CINC-1, secreted by ASCs, played a significant role in promoting recovery by activating key signaling pathways (ERK1/2 and Akt) in the spinal cord, suggesting a mechanism through which ASCs exert their therapeutic effects.
Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury.Ohta, Y., Hamaguchi, A., Ootaki, M., et al.[2018]
In a study involving 10 patients with posttraumatic paraplegia, co-infusion of autologous adipose-derived mesenchymal stem cells (N-Ad-MSC) and hematopoietic stem cells (HSC) into the cerebrospinal fluid was found to be safe, with no adverse effects reported.
Patients showed variable and sustained improvements in their mobility and function over an average follow-up of nearly 3 years, suggesting that stem cell therapy may enhance recovery even after a significant duration post-injury.
Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach.Thakkar, UG., Vanikar, AV., Trivedi, HL., et al.[2020]
Transplanting human adipose tissue-derived mesenchymal stromal cells (hADSCs) into a rat model of spinal cord injury (SCI) resulted in better functional recovery and significant increases in brain-derived neurotrophic factor (BDNF) levels compared to human bone marrow-derived mesenchymal stromal cells (hBMSCs).
hADSCs demonstrated higher proliferative activity and enhanced expression of growth factors, leading to improved angiogenesis, preserved axons, and reduced lesion cavity formation, suggesting they may be a more effective treatment option for SCI than hBMSCs.
Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury.Zhou, Z., Chen, Y., Zhang, H., et al.[2018]

References

Intravenous infusion of adipose-derived stem/stromal cells improves functional recovery of rats with spinal cord injury. [2018]
Infusion of autologous adipose tissue derived neuronal differentiated mesenchymal stem cells and hematopoietic stem cells in post-traumatic paraplegia offers a viable therapeutic approach. [2020]
Comparison of mesenchymal stromal cells from human bone marrow and adipose tissue for the treatment of spinal cord injury. [2018]
The Effects of Adipose Tissue-Derived Mesenchymal Stem Cell Transplantation During the Acute and Subacute Phases Following Spinal Cord Injury. [2018]
Effects of differentiated versus undifferentiated adipose tissue-derived stromal cell grafts on functional recovery after spinal cord contusion. [2021]
CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. [2020]
Intrathecal transplantation of autologous adipose-derived mesenchymal stem cells for treating spinal cord injury: A human trial. [2018]